Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Alternext  >  Biocorp    ALCOR   FR0012788065

BIOCORP

(ALCOR)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Biocorp Production : Launches Inspair, the Smart Sensor to Convert Inhalers into Connected Devices to Help Patients with Asthma or Chronic Obstructive Pulmonary Diseases (COPD)

share with twitter share with LinkedIn share with facebook
10/06/2016 | 02:02am EDT

Regulatory News:

BIOCORP (FR0012788065 – ALCOR / PEA‐PME eligible) (Paris:ALCOR), a French company specializing in the development and manufacturing of medical devices and smart drug delivery systems, today announces the launch of Inspair, the smart sensor which converts inhalers into connected devices to help patients with Asthma or COPD.

Biocorp’s objective is to develop innovative solutions in order to improve treatment compliance by patients suffering from chronic diseases. Significant applications have been developed in diabetology, endocrinology and neurology with the Datapen and Easylog devices, and our new sensor Inspair also positions us in the area of chronic lung diseases which affect an increasing number of people in need of new solutions to improve compliance”, said Jacques Gardette, Biocorp’s Founder and CEO

Asthma is a chronic disease which affects the respiratory tracts: it is characterized by an inflammation and irritation of the bronchial tubes which overreact to various triggers, and causes attacks with typical identifiable symptoms: difficulty in breathing, shortness of breath, dry cough or wheezing.

Asthma is a disease lived by 4 million people in France and 334 million in the world1, and which can rapidly affect the patients’ daily lives if it is not carefully controlled. The compliance and monitoring of the disease are all the more necessary in that a poor management of asthma can rapidly lead to severe asthma responsible for more than 500,000 emergency hospitalization and 1,000 to 1,500 deaths every year in France2. The French health insurance estimates that nearly six in ten people with asthma have inadequate control of their disease and treatment3.

COPD is a chronic lung disease which develops slowly and is characterized by an airway obstruction. It is different from Asthma and usually affects older people suffering from prolonged intoxication, mostly because of smoking (90%). COPD affects about 3 million people in France, and is responsible for more deaths than HIV or Influenza4. A fastidious treatment follow-up with inhaler and/or bronchodilator medication is thus required to reduce symptoms and improve the patient’s quality of life.

Inspair brings an innovative and effective response to the needs of these two pathologies: it acts directly on the treatment compliance and also strengthens the connection between the patient and the medical staff who can provide a real-time therapeutic follow-up. Inspair is a smart sensor capable of converting any pressurized metered dose inhaler into a connected device: it is then able to record data related to the inhalations and to assure an optimal management of the treatment (mastering of the inhalation technique). Equipped with miniaturized sensors and electronic card, Inspair fits on most MDI mouthpieces on the market using specific adaptors. The system automatically records data related to daily inhalations, ensures the right preparation of the canister (shake before usage), assesses the coordination of actuation with inhalation (“hand-mouth” coordination) and also provides with useful guidance throughout the inhalation steps.

Inspair acts on the key levers of the integrated therapeutic education which lowers hospital admissions and calls to emergency services, reduces the frequency of the attacks and other symptoms, and improves the patient’s daily comfort. More than a simple tool for treatment, Biocorp’s connected device becomes an integral part of it.

Still following its Intellectual Property strategy, providing the company with a key competitive advantage, Biocorp has deposited a series of international patents that ensure its full ownership, proof of anteriority and exclusive rights over the exploitation of Inspair.

ABOUT BIOCORP
Founded in 2004 in Issoire (near Clermont-Ferrand), France, Biocorp is a French company specializing in the development and manufacturing of medical devices and innovative drug delivery systems. It is listed as ‘Innovative Company’ by the French public investment bank Bpifrance. With over twenty years of experience and more than 30 manufactured products, Biocorp is a key player in the industry, providing drug delivery solutions that meet the evolving needs of patients. Today, Biocorp continues to innovate in the area of medical plastics, its core business, and to market traditional devices (alternative to aluminum capsules, syringe and vial administration systems) that have been an important source of recurring income. Its solid expertise and capacity to innovate have allowed the company to develop new Internet-connected products, including: the DataPen, a reusable smart injection pen that automatically transmits data to a mobile app, helping patients to manage their treatment; and treatment management add-ons, which adapt to existing delivery devices and are compatible with most injection pens in the market. The company has a team of 44 employees.
Biocorp is listed on Alternext since July 2015 (FR0012788065 – ALCOR).

For more information, please visit: www.biocorp.fr
Follow us on Twitter @BIOCORPSystems

1 Source: http://www.lemonde.fr/sante/article/2016/05/03/quatre-millions-d-asthmatiques-en-france-un-chiffre-sous-estime_4912620_1651302.html#SwIJb5JXKS4Ebi7K.99
2 Source: http://www.lemonde.fr/sante/article/2016/05/03/quatre-millions-d-asthmatiques-en-france-un-chiffre-sous-estime_4912620_1651302.html#SwIJb5JXKS4Ebi7K.99
3 Source: French Institute for Research and Documentation in the Economics of Health (IRDES)
4 Source: COPD French Association


© Business Wire 2016
share with twitter share with LinkedIn share with facebook
Latest news on BIOCORP
06/30BIOCORP : Signs Distribution Agreement for Mallya Technology With Roche Diabetes..
BU
06/22BIOCORP : Announces Initiation of Coverage by Gilbert Dupont
BU
06/19BIOCORP : and Théa Sign a Partnership for the Development of Innovative Digital ..
BU
04/09BIOCORP : 2019 annual results
PU
04/09BIOCORP : 2019 Annual Results
BU
04/09BIOCORP : Annual results
CO
04/06BIOCORP : annual earnings release
02/19BIOCORP : Marketing partnership on Mallya with iSage Rx in the field of digital ..
PU
02/19BIOCORP : Marketing Partnership on Mallya with iSage Rx in the Field of Digital ..
BU
02/12BIOCORP : Strong Revenue Growth In 2019
BU
More news
Financials
Sales 2020 15,3 M 17,2 M 17,2 M
Net income 2020 0,60 M 0,68 M 0,68 M
Net cash 2020 1,17 M 1,32 M 1,32 M
P/E ratio 2020 170x
Yield 2020 0,06%
Capitalization 105 M 119 M 119 M
EV / Sales 2019
EV / Sales 2020 6,82x
Nbr of Employees 52
Free-Float 51,3%
Chart BIOCORP
Duration : Period :
Biocorp Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOCORP
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 2
Average target price 31,35 €
Last Close Price 25,50 €
Spread / Highest target 25,5%
Spread / Average Target 22,9%
Spread / Lowest Target 20,4%
EPS Revisions
Managers
NameTitle
Eric Dessertenne Chief Executive Officer
Jacques Gardette Chairman
Stéphane Chabanais Chief Financial & Administrative Officer
Alain Marcoz Director-Software Research & Development
Emilie Gardette Director
Sector and Competitors
1st jan.Capitalization (M$)
BIOCORP97.67%119
JOHNSON & JOHNSON-2.07%377 458
ROCHE HOLDING AG5.27%299 642
MERCK & CO., INC.-14.33%196 678
NOVARTIS AG-10.23%193 644
PFIZER, INC.-13.86%187 476